Foghorn Therapeutics (FHTX) Income towards Parent Company: 2020-2025
Historic Income towards Parent Company for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -$16.5 million.
- Foghorn Therapeutics' Income towards Parent Company rose 13.87% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.0 million, marking a year-over-year increase of 17.80%. This contributed to the annual value of -$86.6 million for FY2024, which is 11.99% up from last year.
- As of Q3 2025, Foghorn Therapeutics' Income towards Parent Company stood at -$16.5 million, which was up 12.34% from -$18.8 million recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' Income towards Parent Company ranged from a high of -$14.3 million in Q3 2023 and a low of -$30.5 million during Q1 2023.
- Over the past 3 years, Foghorn Therapeutics' median Income towards Parent Company value was -$20.2 million (recorded in 2025), while the average stood at -$21.9 million.
- Per our database at Business Quant, Foghorn Therapeutics' Income towards Parent Company slumped by 68.90% in 2021 and then soared by 44.33% in 2023.
- Foghorn Therapeutics' Income towards Parent Company (Quarterly) stood at -$28.5 million in 2021, then fell by 1.33% to -$28.9 million in 2022, then increased by 16.55% to -$24.1 million in 2023, then increased by 19.09% to -$19.5 million in 2024, then rose by 13.87% to -$16.5 million in 2025.
- Its Income towards Parent Company stands at -$16.5 million for Q3 2025, versus -$18.8 million for Q2 2025 and -$20.2 million for Q1 2025.